Vanessa Ann Fabrizio, MD, MS
Assistant Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation

Photo
Medical School:
  • MD, Drexel University College of Medicine (2014)
Graduate School :
  • MS, Cornell University Weill Graduate School Of Medical Sciences (2020)
Undergraduate School:
  • BS, Purdue University (IN) (2010)
Residency:
  • Medical University of South Carolina Program, Pediatrics (2017)
Fellowships:
  • Memorial Sloan-Kettering Cancer Center/New York Presbyterian Hospital (Cornell Campus) Program, Pediatric Hematology / Oncology (2020)
  • Duke University Hospital Program, Pediatric Transplant and Cellular Therapy (2021)
Languages: English
Department: Pediatrics-Heme/Onc and Bone Marrow Transplantation

Professional Titles

  • Assistant Professor

Recognition & Awards

  • ASTCT Clinical Research Scholar, ASTCT (2022)
  • ISCT Early Stage Professionals Abstract Award, International Society for Cell and Gene Therapy (2021)

Research Interests

My research interests are in improving outcomes for hematologic malignancies with stem cell transplantation and cellular therapies.

Publications

  • Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Adv. 2022 Jan 25;6(2):600-610. PubMed PMID: 34794180
  • Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022 Jul 26;6(14):4251-4255. PubMed PMID: 35580324
  • Schofield HT, Fabrizio VA, Braniecki S, Pelletier W, Eissa H, Murphy B, Chewning J, Barton KD, Embry LM, Levine JE, Schultz KR, Page KM. Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force. Transplant Cell Ther. 2022 Jul 21. [Epub ahead of print] PubMed PMID: 35870778
  • Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Keating AK, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2022 Aug 8. [Epub ahead of print] PubMed PMID: 35938863
  • Schultz LM, Eaton A, Baggott C, Rossoff J, Prabhu S, Keating AK, Krupski C, Pacenta H, Philips CL, Talano JA, Moskop A, Baumeister SHC, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Kunicki M, Mavroukakis S, Egeler E, Li Y, Mackall CL, Curran KJ, Verneris MR, Laetsch TW, Stefanski H. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2022 Sep 15;:JCO2201076. [Epub ahead of print] PubMed PMID: 36108252
  • Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Keating AK, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Egeler E, Mavroukakis S, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2022 Aug 8. [Epub ahead of print] PubMed PMID: 35938863
  • Schofield HT, Fabrizio VA, Braniecki S, Pelletier W, Eissa H, Murphy B, Chewning J, Barton KD, Embry LM, Levine JE, Schultz KR, Page KM. Monitoring Neurocognitive Functioning After Pediatric Cellular Therapy or Hematopoietic Cell Transplant: Guidelines From the COG Neurocognition in Cellular Therapies Task Force. Transplant Cell Ther. 2022 Jul 21. [Epub ahead of print] PubMed PMID: 35870778
  • Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Guest EM, Breese EH, Schultz LM. Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022 Jul 26;6(14):4251-4255. PubMed PMID: 35580324
  • Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2022 Mar 20;40(9):945-955. PubMed PMID: 34882493
  • Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Adv. 2022 Jan 25;6(2):600-610. PubMed PMID: 34794180
  • Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta H, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. Blood Adv. 2022 Apr 12;6(7):1961-1968. PubMed PMID: 34788386
  • Fabrizio VA, Rodriguez-Sanchez MI, Mauguen A, Dahi PB, Doubrovina E, O'Reilly RJ, Prockop SE. Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses. Blood Adv. 2021 Jan 26;5(2):496-503. PubMed PMID: 33496746
  • Sabnis HS, Shulman DS, Mizukawa B, Bouvier N, Zehir A, Fangusaro J, Fabrizio VA, Whitlow C, Winchester M, Agresta L, Turpin B, Wechsler DS, DuBois SG, Glade-Bender J, Castellino SM, Shukla N. Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. J Clin Oncol. 2021 Sep 30;:JCO2101213. [Epub ahead of print] PubMed PMID: 34591650
  • Rossoff J, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Kunicki M, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Out of Specification Tisagenlecleucel Does Not Compromise Safety or Efficacy in Pediatric Acute Lymphoblastic Leukemia. Blood. 2021 Sep 9. [Epub ahead of print] PubMed PMID: 34499715
  • Fabrizio VA, Curran KJ. Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia. Best Pract Res Clin Haematol. 2021 Sep;34(3):101305. PubMed PMID: 34625231
  • Fabrizio VA, Boelens JJ, Mauguen A, Baggott C, Prabhu S, Egeler E, Mavroukakis S, Pacenta HL, Phillips CL, Rossoff J, Stefanski H, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston ML, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Chinnabhandar V, Kunicki M, Goksenin AY, Mackall CL, Laetsch TW, Schultz LM, Curran KJ. Optimal fludarabine lymphodepletion is associated with improved outcomes following CAR T-cell Therapy. Blood Adv. 2021 Nov 17. [Epub ahead of print] PubMed PMID: 34788386
  • Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, Laetsch TW. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. J Clin Oncol. 2021 Dec 9;:JCO2003585. [Epub ahead of print] PubMed PMID: 34882493
  • Fabrizio VA, Kernan NA, Boulad F, Cancio M, Allen J, Higman M, Margossian SP, Mauguen A, Prockop S, Scaradavou A, Shah N, Spitzer B, Stieglitz E, Yeager N, O'Reilly RJ, Brentjens RJ, Jan Boelens J, Curran KJ. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2020 Nov;55(11):2160-2169. PubMed PMID: 32390002
  • Fabrizio V, Wahlquist A, Hill E, Williams E, Kramer C, Jaroscak J, Duong A, Garrett-Mayer E, Hudspeth M. The effect of bone marrow graft composition on pediatric bone marrow transplantation outcomes. Pediatr Transplant. 2018 Dec;22(8):e13287. PubMed PMID: 30159974
View All (19 Total) View Less

Professional Memberships

  • Children's Oncology Group, Member
  • American Society for Transplantation and Cellular Therapy, Member
  • American Society of Hematology, Member

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation
  • Children's Hospital Colorado
Center Affiliations

Specialty Information

Specialties
  • Pediatrics, Board Certification (2017)
  • Pediatric Hematology / Oncology, Board Certification (2021)
Conditions & Treatments
  • Cancers - Blood and Marrow Transplant
  • Cancers
  • Cancers - Leukemia (Childhood)
  • Cancers - Pediatric Cancer
Clinical Interests
My clinical interests include pediatric stem cell transplantation and cellular therapies for malignant diseases, particularly hematologic malignancies.

Care Philosophy
My goal is to ensure all patients and their families feel heard and I understand their unique experiences with past treatment and goals for future treatment. Our entire team is dedicated to providing the best care possible for each patient and their families with more effective and less toxic therapies.

Personal Interests
I enjoy traveling around the world with my husband, hiking with our chocolate lab, and eating at great restaurants.

Public Speaking
Yes

General Information

Medical Schools:
  • MD, Drexel University College of Medicine (2014)
Graduate Schools:
  • MS, Cornell University Weill Graduate School Of Medical Sciences (2020)
Undergraduate Schools:
  • BS, Purdue University (IN) (2010)
Residency Programs:
  • Medical University of South Carolina Program, Pediatrics (2017)
Fellowships:
  • Memorial Sloan-Kettering Cancer Center/New York Presbyterian Hospital (Cornell Campus) Program, Pediatric Hematology / Oncology (2020)
  • Duke University Hospital Program, Pediatric Transplant and Cellular Therapy (2021)
Languages: English
Department: Pediatrics-Heme/Onc and Bone Marrow Transplantation
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;